NEW YORK (360Dx) – Itus said today it has renewed a collaborative agreement with the Wistar Institute for the development of its Cchek early cancer detection technology.

Itus is developing the Cchek platform through Anixa Diagnostics, its subsidiary. The platform is a series of non-invasive blood tests for the early detection of solid tumor cancers based on the body's immunological response to malignancy.

Itus Chairman and CEO Amit Kumar said in a statement, "Wistar's R&D support has been and continues to be valuable to the development of Cchek."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.